跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PERGOVERIS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
PERGOVERIS
Authorized
STANDARD
PERGOVERIS
emd serono, a division of emd inc., canada
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
3a89335aa0b3a117
Company
emd serono, a division of emd inc., canada
Type
Standard
Approval Details
Approval Id
3a89335aa0b3a117
Drug Approval Canada Name
PERGOVERIS
Product Name
PERGOVERIS
Status
Marketed
Status Date
2021-10-29
Original Market Date
2021-10-29
Din
02470659
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
68:18.00
Atc Original
G03GA30 COMBINATIONS
Atc Name
g 03 ga 30
Aig Number
0257310002
Company Name
emd serono, a division of emd inc., canada
Company Address
2695 North Sheridan Way, Suite 200, Mississauga, Ontario, Canada, L5K 2N6
Active Ingredients
FOLLITROPIN ALFA
450 UNIT / 0.72 ML
LUTROPIN ALFA
225 UNIT / 0.72 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
3a89335aa0b3a117
Type
Standard
Back to Health Canada Approvals